Pharmacoepidemiology involves applying epidemiological methods to study drug use and effects in large populations. It is primarily concerned with post-marketing drug safety surveillance but also analyzes patterns of drug use and assesses effectiveness. Pharmacoepidemiological studies use large healthcare databases and are important for identifying adverse drug reactions, determining risk factors, and improving appropriate medication use. Common study designs include cohort studies, case-control studies, and randomized controlled trials. Pharmacoepidemiology plays a key role in drug regulation, marketing, clinical practice, and public health policy.
breif notes on what is pharmacoepidemiology, why do we need pharmacoepidemiology, whats is its aim and its main applications, advantages and disadvantages
Pharmacoepidemiology is the study of effects of drugs in large numbers of people.
Epidemiologic Study Designs, Reasons to perform Pharmacoepidemiology studies, Users of pharmacoepidemiology and Role of Pharmacists & other Public Health Practitioners in Pharmacoepidemiology are discussed in this presentation.
Genetic polymorphism in drug transport and drug targets.pavithra vinayak
Genetic polymorphism in drug transport and targets.--pharmacogenetics
DRUG TRANSPORTER
Two types of transporter :
•ATP binding Cassette (ABC) – Found in ABCB, ABCD and ABCG family. Associated with multidrug resistance (MDR) of tumor cells causing treatment failure in cancer.
•Solute Carrier (SLC) – Transport varieties of solute include both charged or uncharged
P-glycoprotein
• ATP binding cassette subfamily B member- 1 (ABCB 1)
• Multidrug resistance protein 1 (MDR1)
• Transport various molecules, including xenobiotic, across cell membrane
• Extensively distributed and expressed throughout the body
Mechanism of Pglycoprotein
Substrate bind to P-gp form the inner leaflet of the membrane
ATP binds at the inner side of the protein
ATP is hydrolyzed to produce ADP and energy
Definition and scope of Pharmacoepidemiology ABUBAKRANSARI2
In these slides I shared the information of definition and scope of pharmacoepidemiology. Types of studies - cohort studies, cross-sectional studies etc.
various measures for the measurement of outcome such as incidence prevalence and other drug us measures are briefly discussed here with suitable examples and equations
breif notes on what is pharmacoepidemiology, why do we need pharmacoepidemiology, whats is its aim and its main applications, advantages and disadvantages
Pharmacoepidemiology is the study of effects of drugs in large numbers of people.
Epidemiologic Study Designs, Reasons to perform Pharmacoepidemiology studies, Users of pharmacoepidemiology and Role of Pharmacists & other Public Health Practitioners in Pharmacoepidemiology are discussed in this presentation.
Genetic polymorphism in drug transport and drug targets.pavithra vinayak
Genetic polymorphism in drug transport and targets.--pharmacogenetics
DRUG TRANSPORTER
Two types of transporter :
•ATP binding Cassette (ABC) – Found in ABCB, ABCD and ABCG family. Associated with multidrug resistance (MDR) of tumor cells causing treatment failure in cancer.
•Solute Carrier (SLC) – Transport varieties of solute include both charged or uncharged
P-glycoprotein
• ATP binding cassette subfamily B member- 1 (ABCB 1)
• Multidrug resistance protein 1 (MDR1)
• Transport various molecules, including xenobiotic, across cell membrane
• Extensively distributed and expressed throughout the body
Mechanism of Pglycoprotein
Substrate bind to P-gp form the inner leaflet of the membrane
ATP binds at the inner side of the protein
ATP is hydrolyzed to produce ADP and energy
Definition and scope of Pharmacoepidemiology ABUBAKRANSARI2
In these slides I shared the information of definition and scope of pharmacoepidemiology. Types of studies - cohort studies, cross-sectional studies etc.
various measures for the measurement of outcome such as incidence prevalence and other drug us measures are briefly discussed here with suitable examples and equations
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimenpavithra vinayak
conversion from INTRAVENOUS TO ORAL DOSING----- TYPES OF IV TO PO THERAPY CONVERSIONS: MEDICATIONS INCLUDED IN AN IV TO PO CONVERSION PROGRAM: SELECTION OF PATIENTS FOR IV TO PO THERAPY CONVERSION: design of dosage regimen--clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
Population pharmacokinetics is the study of the sources and correlates of variability in drug concentrations among individuals who are the target patient population receiving clinically relevant doses of a drug of interest
adaptive methods are doing with feedback in population pharmacokinetics---- clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
Pharmacological Approach to Drug DiscoverySuhas Reddy C
For better understanding of students. This will give you a detailed explanation of Pharmacological approach. Contact me through comment section if you need any assistance in understating
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimenpavithra vinayak
conversion from INTRAVENOUS TO ORAL DOSING----- TYPES OF IV TO PO THERAPY CONVERSIONS: MEDICATIONS INCLUDED IN AN IV TO PO CONVERSION PROGRAM: SELECTION OF PATIENTS FOR IV TO PO THERAPY CONVERSION: design of dosage regimen--clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
Population pharmacokinetics is the study of the sources and correlates of variability in drug concentrations among individuals who are the target patient population receiving clinically relevant doses of a drug of interest
adaptive methods are doing with feedback in population pharmacokinetics---- clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
Pharmacological Approach to Drug DiscoverySuhas Reddy C
For better understanding of students. This will give you a detailed explanation of Pharmacological approach. Contact me through comment section if you need any assistance in understating
Pharmacoeconomics is a branch of health economics which compares the value of one drug or a drug therapy to another.
By understanding the principles, methods, and application of pharmacoeconomics, healthcare professionals will be prepared to make better decisions regarding the use of pharmaceutical products and services.
To study new drug registration process in u.sManoj Dagwar
Legislative History of Drug Regulation
Derived from the Dutch word meaning to boast (quacken), “quack” is the word Americans have commonly used to describe charlatans in medicine. Quacks peddled adulterated and mislabeled Medicines throughout the United States without penalty until 1906, when Congress passed the Food and Drugs Act, one section of which outlawed the practice.
Over the next half-century, Congress passed two major pieces of legislation expanding FDA Authority. It passed the Federal Food, Drug, and Cosmetic Act (FFDCA) in 1938, requiring that
Drugs be proven safe before they could be sold in interstate commerce. Then, in 1962, in the wake of deaths and birth defects from the tranquilizer thalidomide marketed in Europe, Congress passed the Kefauver-Harris Drug Amendments to the FFDCA,3 increasing safety provisions and
Requiring that drugs be proven effective as well.
Congress has amended the FFDCA many times, leading to FDA’s current mission of assuring
Americans that the medicines they use do no harm and actually work—that they are, in other words, safe and effective. In recent decades Congress has passed additional laws to boost
Pharmaceutical research and development and to speed the approval of new medicines.
FDA also regulates products other than drugs—for example, biological products, medical devices,
Dietary supplements, foods, cosmetics, animal drugs, and tobacco products. Sometimes the
Agency addresses issues that straddle two or more product types that the law treats differently.
How FDA Approves New Drugs
To market a prescription drug in the United States, a manufacturer needs FDA approval. to get that approval, the manufacturer must demonstrate the drug’s safety and effectiveness according to criteria specified in law and agency regulations, ensure that its manufacturing plant passes FDA inspection and obtain FDA approval for the drug’s labeling—a term that includes all written material about the drug, including, for example, packaging, prescribing information for physicians, and patient brochures.
The approval process begins before the law requires FDA involvement. Figure 1 illustrates a product’s timeline both before and during FDA involvement.
The research and development process for a finished drug usually begins in the laboratory. Basic research is often conducted or funded by the federal government.7 when basic research yields an idea that someone identifies as a possible drug component, government or private research groups focus attention on a prototype design. At some point, private industry (either a large, established company or a newer, smaller, start-up company) continues to develop the idea, eventually testing the drug in animals. When the drug is ready for testing in humans, the FDA must get involved.
The Standard Process of Drug Approval
The four FDA steps leading to the agency’s approval of a new drug for marketing in the United
States are described below.
With MiFID II just round the corner, the need to consider how to meet regulatory demands on the recording of telephone conversations and electronic communications is imminent. Here are our top 6 compliance-driven solutions to consider.
Journal of Advances in Pharmacoepidemiology and Drug SafetyOMICS International
OMICS Publishing Group journal, Advances in Pharmacoepidemiology and Drug Safety is a peer-reviewed, open access journal that publishes original research articles dealing with all aspects of research on the use and effects of drugs in large numbers of people and drug safety. The emphasis is on publishing quality papers quickly and making them easily accessible to researchers all over the world.
Epidemiology is the study of occurrence, distribution and determinants of health and
diseases or disorders in man and its application in controlling health problems.
Epidemiology has by tradition two major areas.
First is the study of infectious diseases that spread to large populations, i.e., epidemics.
The second is the study of chronic diseases.
Epidemiological studies help to solve such health problems and provide a basis for
improving living conditions of the people.
During its progress and development, epidemiology has made available precise and
strict methodologies for the study of diseases.
Pharmacology is the study of the effects of drugs.
Clinical Pharmacology is the study of the effects of drugs in humans, It is traditionally
divided into two basic areas namely:
1. Pharmacokinetics
2. Pharmacodynamics.
Pharmacokinetics is the study of the relationship between dose administered of a drug
and the serum or blood level achieved, it deals with absorption, distribution, metabolism
and excretion.
Epidemiology is the study of the distribution and determinants of diseases in
populations.
Epidemics is the study of chronic/ infectious diseases in large populations.
Pharmacoepidemiology is the study of the use of and the effects of drugs in large
number of people.
It involves the examination of a single individual or large groups of people followed for
many years.
It involves gathering & analysis of information in order to identify possible causation &
related factors, that can be applied in clinical practice to group of people & also to
individuals undergoing treatment.
The safe use of medicines is perhaps the single most important criteria that any regulatory authority within a given country has to ensure in order both to protect the public health and the integrity of its health care system. For the same purpose pharmacovigilance was established. According to WHO, Pharmacovigilance is the science and activities related to the collection, detection, and assessment of ADR’s. It promotes the systematic, rational use and assures the confidence for the safety of drugs. It improves patient care and safety. Significance of pharmacovigilance is growing as the patients or consumers have become more responsive about the advantage and hazard of medicines. Pharmacovigilance is a complex process and a robust system is essential to undertake the activity. A good pharmacovigilance system will identify the hazard aspects in the short period of time. This review article tries to explain the some basic principles, history and developments, methods and some scope of this developing field i.e. Pharmacovigilance in India.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
2. Introduction
Application of epidemiological methods to the clinical use and
effects of drugs in a large population is called as
Pharmacoepidemiology.
Pharmacoepidemiology was primarily concerned with post-
marketing studies of drug safety.
Pharmacoepidemiology research is often based on large health care
utilization databases using non experimental study of intended and
unintended drug effects outside of randomized controlled trials.
In addition to identifying adverse events, one of the key objectives of
Pharmacoepidemiology is to identify reasons that may explain the
adverse events. These questions can include:
Pharmacoepidemiology.
3. Are the events dose related?
Does the pharmaceutical interact with other
medications or substances to promote adverse events?
Are there high-risk subpopulations or pertinent
lifestyle factors that can be identified as being related to
the event?
Are drugs being used differently than originally
intended
4. Furthermore, it also define patterns of physicians’ prescription and
patients’ use and compliance of medications.
Analyze the influence of health system factors (policies, coverage
and reimbursement differences) on the quality of medication use.
Design, implement, and test innovative programs to improve the
appropriateness of medications prescribed by physicians and used
by patients.
5.
6. Short duration Premarketing studies are limited in time. Effects that develop
following chronic use or those that have a long latency period
cannot be detected
Small sample size Few drugs are studied in more than 4,000 subjects before FDA
approval. Effects that occur with a frequency of less than
1/1,000 are difficult to detect.
Narrowly defined
population
Premarketing studies generally do not include special
populations such as children, women of childbearing
age, or the elderly.
Narrow set of
indications
Manufacturers pursue specific indications for use during
premarketing studies.
Limited
comparison
groups
The comparison group is often limited to placebo.
Limitations of Premarketing Clinical Trials
7. • About 20% of drugs get new “black box”
warnings after marketing
• About 4% of drugs are ultimately
withdrawn for safety reasons
Consequences of Limitations of Pre-marketing
Trials
8. •Suicidal tendency increased tendency associated to the use of fluoxetine and other
SSRI antidepressants
•Tardive dyskinesia associated with long-term use of metoclopramide and many
antipsychotic
•Stroke or heart attack associated with sildenafil (Viagra) when used with
nitroglycerine
•Cerivastatin. Treatment of hypelipdeimeia
•Introduced in 1990s, withdrawn in 2001
•Why ? , 52 deaths were reported from rhabdomyolysis and its resultant renal
failure
•The story of thalidomide is well known
•Chloramphenicol and Grey Baby Syndrome
•Gynaecological cancer in offspring of women receiving Diethyl Stilboestrol
•Oculomucocutaneous syndrome with practolol
•Liver disease from benoxaprofen
•Valvular heart disease from Dexfenfluramine
•Cardiac arrhythmias with terfenadine
Despite the rigorous process for drug approval and regulation, several
important medications have been removed from the market because of serious
ADEs over the past 30 years as a result of Pharmacoepidemiological studies
9. Pharmacoepidemiological consulting services on numerous projects
also provided supportive evidences. Some examples include:
Cardiovascular risk among women using dietary supplements
Liver failure risks among users of anticonvulsants
Clinical and economic impacts on asthma and COPD of a new
respiratory bronchodilator
Costs associated with complications after cataract surgery
Effectiveness of adding omega-3 supplements to diet
Projection of future needs, clinical trends, and economic impact for
knee and hip replacement surgery
Assessment of potential patient population size for proposed orphan
drug application and filing of Pediatric Investigation Plan
Epidemiologic evaluation of factors influencing patterns of care in
chemotherapy treatment for common female cancers,
Beneficial findings of Pharmacoepidemiological studies
10. Aim of Pharmacoepidemiology
• Signal Generation: Most commonly associated with
ADR but also use to detect new applications
– E.g Minoxidil 1st indicated for hypertension but
case report (signal generation) soon identified it
causes hirsutism in a number of patients, side
effect was investigated and now it is marketed for
purpose mainly stimulation of hair growth
• Risk Quantification: of ADR often require large
sample size
11. Hypothesis testing
Require the use of comparison group to determine
whether there are difference in variable of interest (risk
factor, trait, characteristic, drug exposed, or clinical
conditions)
Statistical methods are used to assess whether the
observed difference could have occur by chance alone
Conclusions about relation b/w exposure to a drug and
clinical event thus based on the ability to reject the null
hypothesis, postulating that the 2 group are no difference
with regard to either the drug exposure or the clinical
event
12. Example: Signal identified via spontaneous reporting
confirmed by a formal Pharmacoepidemiology study.
Background-
•Phenylpropanolamine (PPA)- ingredient used in OTC and
prescription cough and cold medications as a decongestant, and
in OTC weight loss products.
•In 1984, FDA received reports of Hemorrhagic stroke (bleeding
into brain or into tissue surrounding brain) in association with
PPA.
•In addition, there were published reports in literature.
•Question-
•Is the use of PPA-containing products associated with
hemorrhagic stroke?
13. Approach-
To confirm this signal, an ad-hoc case-control study was
conducted
Results
The study demonstrated a statistically significant increased risk of
hemorrhagic stroke among both appetite suppressant users and
first-time users of PPA as cough/cold remedy
Outcome-
FDAAdvisory Committee meeting discussed the case-control
study and recommended that PPA be considered not safe for
OTC use
FDA then took steps to remove PPA from all drug products and
requested all drug companies to discontinue or reformulate PPA-
containing products.
14. Reasons to perform PE studies:
(A) Regulatory
(1) Required to obtain earlier approval for marketing
(2) As a response to question by regulatory agency
(3) To assist application for approval for marketing elsewhere
15. (B) Marketing
(1) To assist market penetration by documenting the safety of the
drug
(2) To increase name recognition
(3) To assist in repositioning the drug
(a) Different outcomes, e.g., quality-of-life and economic
(b) Different types of patients, e.g., the elderly
(c) New indications
(d) Less restrictive labeling
(4) To protect the drug from accusations about adverse effects
(C) Legal
(1) In anticipation of future product liability litigation
16. (D) Clinical
(1) Hypothesis testing
(a) Problem hypothesized on the basis of drug structure
(b) Problem suspected on the basis of preclinical or premarketing
human data
(c) Problem suspected on the basis of spontaneous reports
(d) Need to better identify the frequency of adverse reactions
(2) Hypothesis generating—need depends on:
(a) whether it is a new chemical entity
(b) the safety profile of the class
(c) the relative safety of the drug within its class
(d) the formulation
(e) the disease to be treated, including
(i) its duration
(ii) its prevalence
(iii) its severity
(iv) whether alternative therapies are available
17. Thus, the decision to conduct a PE study can be viewed as similar
to the regulatory decision about whether to approve a drug for
marketing or the clinical decision about whether to prescribe a
drug.
In both cases, decision making involves weighing the costs and
risks of a therapy against its benefits.
18. Application of Pharmacoepidemiology
• Estimation of risk of drug use
• Use in patient counseling
• Formulation of public health policy decision
• Formulation of therapeutic guidelines and discovery
of new indications
• Facilitate thepharmaco-economic evaluation
19.
20.
21. Pharmacoepidemiology in Practice
• The basic idea of pharmacoepidemiology is to
measure the source, use, and effects of drugs in a
population and to determine the frequency and
distribution of drug use outcomes in that population
22. The focus of this type of research includes
(1) what is being used (an assessment of specific
drugs being used in certain situations)
(2) How it is being used (an assessment of the
patterns of use, including how much, where and
when, and by whom); and
(3) Why it is being used (an assessment of the reasons
for drug-taking behaviors and the functions that
drugs serve in society).
23. World Health Organization
WHO focuses its pharmacoepidemiological efforts on ensuring the
quality, safety, and efficacy of drugs and their use in specific
populations and studies are performed to :
1) Describe current patterns of drug use in specific patient
populations
2) Determine changes in drug use over time
3) Measure the effects of information, education, promotional
activities, media accounts, and price on drug use
4) Detect inappropriate drug use and associated problems
5) Estimate drug needs in terms of disease patterns and outbreaks
6) Plan the selection, supply, and distribution of drugs.
24. Research methods used most often by
pharmacoepidemiologists
• Cross-sectional study: a prevalence survey of health
and illness in the population at one point in time
• Case-control study, a retrospective analysis comparing
subjects with the condition (cases) to those without it
(controls) with respect to possible risk or causative
factors
• Cohort study, an incidence study that follows a
population free of health problems over time,
examining subsequent development of problems and
factors associated with them.
• Clinical trials, an experimental approach that tests the
value of a new treatment or intervention compared
with a standard treatment or a placebo, are also
considered to be an epidemiological method
25. Thus, Pharmacoepidemiology relies on the same study designs
(cohort, case control, case-crossover, case-cohort studies), as other
branches of epidemiology.
The field also offers unique challenges in:
Controlling For Confounding Factors
Addressing The Limitations Of Health Care Databases
Obtaining Accurate Assessment Of Drug Exposure And Use
Accounting For Potential Selection Bias Concerns.
Common research methods used by Pharmacoepidemiologists –
Cont’d
Moreover, Pharmacoepidemiological studies provide "real
world" assessments of potential short-term and long-term
adverse drug events in the general population with a wide range
of health status and demographic characteristics and with a
much longer follow-up period than clinical trials, which
evaluate initial drug efficacy and safety.
26. Sources of Data on Drug Use
• Institutional record systems and databases
– Drug utilization studies
– Hospital-based medical audits (inpatient)
• System wide databases
– Institutionally based reviews (outpatient)
– Health insurance groups and third-party payers
– Pharmaceutical organizations
– Commercial vendors of marketing studies and
sales data
27. • National databases
– government-sponsored studies
– essential drug lists and inventory data
– pharmacoepidemiological surveillance systems
• Field data
– records of drug dispensers, sellers, and distributors
– drug-taking behaviors of individuals and small
groups
• Experimental data
– clinical trial results
Sources of Data on Drug Use- Cont’d
28. Problem Solving with Pharmacoepidemiology
Medical drug use
Beneficial effects of drug therapy
Risks (e.g., adverse reactions, side effects) of drug
therapy
Inappropriate prescribing behaviours
Patient noncompliance
Irrational self-medication practices
Poor drug use outcomes
Cost-effectiveness of drug therapy
29. Problem Solving with Pharmacoepidemiology- Cont’d
Nonmedical drug use
Social-recreational drug use and associated
problems
Acute incidents of drug toxicities (e.g., overdoses)
Chemical dependencies
Outbreaks and sources of drug epidemics
30. Conclusion
All drugs have adverse effects and Pharmacoepidemiology will
never succeed in preventing them.
It can only detect them, hopefully early, and thereby educate health -
care providers and the public, which will lead to better medication
use.
The net results of increased activity in pharmacoepidemiology will
be better for industry and academic world but, most importantly, for
the public’s health.
The next drug disaster cannot be prevented by
pharmacoepidemiology. However, pharmacoepidemiology can
minimize its adverse impact by detecting it early.
The past few decades have demonstrated the utility of this new
field.
With good fortune, the next few years will see the utility is
accentuated and the problems will be improved.